Cardiff Oncology Announces Plans For A Randomized Trial, Durability Of Responses In Ongoing Phase 1b/2 Trial In Metastatic Colorectal Cancer And Additional Business Updates
Next trial in RAS-mutated mCRC (ONSEMBLE) is a randomized Phase 2 trial to demonstrate onvansertib's contribution to SoC and position for a possible accelerated approval opportunity; topline data expected in 2H
Adamis Provides An Enrollment Update On The Phase 2/3 Study Of Tempol In COVID-19 Positive High-Risk Subjects
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19 has reached the
PolyPid Earlier Announces Presentation Of Phase 2 D-PLEX₁₀₀ Clinical Data At The European Society For Coloproctology Scientific Conference Sept 21-23
Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection will be Presented During a Podium Presentation
BioMarin Says One Participant Diagnosed With Leukemia In Late-Stage Hemophilia Gene Therapy Trial
In an SEC filing, BioMarin Pharmaceutical Inc (NASDAQ:BMRN) said that, in August, a participant in its valoctocogene roxaparvovec (BMN 270)…
Avalon Globocare Has Received A Notice Of Allowance For Its U.S. Patent Application 17/210,837 Titled “Qty Fc Fusion Water Soluble Receptor Proteins (For The Treatment Of Cytokine Release Syndrome)”
https://twitter.com/PatentGrants/status/1569347853348388864
https://patentcenter.uspto.gov/applications/17210837/ifw/docs
NuCana Presents Data On NUC-7738 At The European Society Of Medical Oncology Annual Meeting 2022
NUC-7738 Demonstrates Encouraging Anti-Tumor Activity and a Favorable Safety Profile Across a Variety of Solid Tumors
NUC-7738 Monotherapy and Combination with Pembrolizumab to be Investigated in Phase 2
PARIS,
Natera Presents New Colorectal And Breast Cancer Data From The CIRCULATE-Japan Study At ESMO
Data from the largest real-world MRD study to date in resectable colorectal cancer reinforces the findings from the recent CIRCULATE-Japan study
AUSTIN, Texas, Sept. 12, 2022 /PRNewswire/ -- Natera,
Novavax Nuvaxovid COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization In The European Union For Use As A Booster For Adults Aged 18 And Older
Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC) has
U.S. FDA Accepts Acadia’s Filing For Rett Syndrome Candidate Under Priority Review
The U.S. Food and Drug Administration (FDA) has accepted for filing Acadia Pharmaceuticals’ (NASDAQ: ACAD) New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome.
The regulatory agency has granted a priority review and assigned a PDUFA action date of March 12, 2023.